JP MORGAN/CALL/VERTEX PHARMACEUTICALS/400/0.1/17.01.25 | Market Closed - Börse Stuttgart 03:03:47 26/06/2024 pm IST | ||
| 9.13 EUR | -1.72% |
|
| Current month | +27.16% | ||
| 1 month | +17.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 9.13 | -1.72% |
| 25/24/25 | 9.29 | +4.26% |
| 24/24/24 | 8.91 | -2.73% |
| 21/24/21 | 9.16 | +6.26% |
| 20/24/20 | 8.62 | -1.03% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 03:03 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL07U7 |
| ISIN | DE000JL07U70 |
| Date issued | 12/04/2023 |
| Strike | 400 $ |
| Maturity | 17/01/2025 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 3.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.17 € |
|---|---|
| Lowest since issue | 3.32 € |
| Spread | 0.3 € |
| Spread % | 3.16% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Warrants
- Warrant
